Abstract: The presentation of eosinophilic esophagitis (EoE) is heterogeneous with varied clinical, endoscopic, and histologic features impacting the severity of the condition. Until recently, however, and in contrast with many other conditions, there has been no standardized way to measure disease severity in EoE. A clinically applicable method for assessing severity in routine practice has been recognized as necessary to standardize assessment and management of EoE. Therefore, the American Gastroenterological Association has sponsored a consensus conference to determine elements of severity in EoE and develop the first tool to measure severity. This article presents details of this severity metric, which…
Author: Abhay Panchal
Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated. That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug…
Three primary stakeholders may play a role in protecting patients from the infection risk associated with reusable gastroscopes: healthcare providers, endoscope manufacturers and the U.S. Food and Drug Administration. Dr. Lawrence Muscarella, a national authority on the causes and prevention of healthcare-associated infections, offered advice to those stakeholders on the Transmission Control podcast in the third episode of a three-part series on gastroscope safety signals.
A Louisiana woman is suing the makers of two type 2 diabetes drugs used off-label for obesity, saying they failed to adequately warn about the risk of severe stomach problems. The lawsuit seeks “very significant” but unspecified compensation from the makers of both Ozempic and Mounjaro, said attorney Paul Pennock of the Orlando, Fla.-based firm Morgan & Morgan.
In a Healio video exclusive, Edward V. Loftus Jr., MD, highlighted the growing recognition that diet, specifically tailored nutrition interventions, can play a crucial role in the management of several gastrointestinal disorders. “We all know, especially in [inflammatory bowel disease], the re-emerging of diet as an important factor in terms of how to manage patients, and I think that recognition has played out in other parts of GI as well,” Loftus, the Maxine and Jack Zarrow Family Professor of Gastroenterology at the Mayo Clinic told Healio.
Compare hospital ratings for gastroenterology and GI surgery. U.S. News evaluated 1,581 hospitals and ranked the top 50 that treat many challenging patients for stomach, esophageal, digestive, pancreatic, liver, colon, bowel and rectal procedures and conditions such as IBD, cirrhosis and hepatitis.
Colon cancer remains the second deadliest cancer in the U.S. in 2023, but it has a 90 percent survival rate with early detection and treatment. In the last year, five celebrities have publicly shared their colonoscopy journeys in an effort to encourage the general public to get checked for colorectal cancer.
Some clinicians say it’s “confusing” and “ridiculous” to change the name and diagnostic criteria of an established liver disease, while others bemoan the seemingly political reasons why it happened. Yet recently, 236 panelists from 56 countries decided that the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) rely on “exclusionary confounder terms and the use of potentially stigmatizing language.” In a report published June 24 in the Journal of Hepatology, the panelists, members of the NAFLD Nomenclature Consensus Group, determined that steatotic liver disease (SLD) would be used as an “overarching term to encompass the various etiologies of…
IBS is a symptom-based disorder characterized by recurring bouts of abdominal pain and altered bowel habits. IBS is prevalent, negatively affects quality of life and work productivity, and accounts for billions of dollars in healthcare expenditures. IBS is effectively treated with individualized combinations of medications, diet changes and behavioral interventions. The review is intended to familiarize gastroenterologists with the current generation of DTx that provide virtual behavioral health interventions for patients with IBS.
A clinical trial is one of the most essential steps in the pharmaceutical/biotechnology research and development process, yet one of the biggest stumbling blocks historically has been finding and retaining patients to participate in studies. The answer to that problem could lie in helping more physicians integrate clinical trials into their private community practices to make it a natural extension of the routine care they provide their patients.